Cas:64228-79-1 atracurium manufacturer & supplier

Chemical Name:atracurium

CAS.NO:64228-79-1

Synonyms:5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate;2,2′-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium];Isoquinolinium, 2,2′-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-;Atracurium;2,2′-{Pentane-1,5-diylbis[oxy(3-oxopropane-3,1-diyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium];UNII-2GQ1IRY63P;Atracurium Dibesylate

Molecular Formula:C₅₃H₇₂N₂O₁₂++

Molecular Weight:929.144

HS Code:

Physical and Chemical Properties:

Melting point:185-194ºC

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:126.44000

Exact Mass:928.507446

LogP:1.04

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-[3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoyloxy]pentyl 3-[1-[(3,4-dimethoxyphenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propanoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Atracurium Dibesylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,UNII-2GQ1IRY63P Use and application,2,2′-{1,5-Pentanediylbis[oxy(3-oxo-3,1-propanediyl)]}bis[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolinium] technical grade,usp/ep/jp grade.

Related News: Earlier this year, the US Food and Drug Administration approved Verquvo to reduce the risk of cardiovascular death and heart failure hospitalisation, following a hospitalisation for heart failure or need for outpatients intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. 4,4′-(p-Methoxyphenyl)methyliden-bis(3-acetamido-1-phenyl-2-pyrazolin-5-on) manufacturers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, 2,4-dibromophenyl-thioacetic acid suppliers The US-based study is evaluating the effect of ensifentrine on key outcomes in patients hospitalised with COVID-19, including facilitation of recovery from the viral infection, clinical status improvement and reduction in supplemental oxygen use and progression to mechanical ventilation. 1,1′-[1-(p-toluenesulfonyl)hydrazono-3-phenyl-propane-1,3-diyl]-ferrocene vendor & factory.